2024
MIF contribution to progressive brain diseases
Matejuk A, Benedek G, Bucala R, Matejuk S, Offner H, Vandenbark A. MIF contribution to progressive brain diseases. Journal Of Neuroinflammation 2024, 21: 8. PMID: 38178143, PMCID: PMC10765708, DOI: 10.1186/s12974-023-02993-6.Peer-Reviewed Original ResearchConceptsBrain diseasesMultiple sclerosisAlzheimer's diseaseMacrophage migration inhibitory factorModulation of neuroinflammationNumerous neurologic diseasesMigration inhibitory factorProgressive brain diseaseNew therapeutic strategiesInflammatory mediatorsChronic inflammationAutoimmune diseasesVascular diseaseNervous system developmentNeurologic diseaseNeuroendocrine functionPsychiatric disordersTherapeutic strategiesEconomic burdenNeurological diseasesNew biomarkersInhibitory factorNeurodegenerative pathologiesDiseaseNovel therapeutics
2019
Immunoepidemiology of Mycobacterium tuberculosis
Odio C, Bucala R. Immunoepidemiology of Mycobacterium tuberculosis. 2019, 151-163. DOI: 10.1007/978-3-030-25553-4_9.Peer-Reviewed Original ResearchHuman leukocyte antigenMycobacterium tuberculosisLatent Mycobacterium tuberculosisRole of nutritionNumber one causeRegional infectious diseasesHuman immune systemActive diseaseVitamin DLeukocyte antigenRisk factorsDisease presentationClinical diversityInfectious agentsOne causeImmune systemHost defenseInfectious diseasesImmunoepidemiologyImmune proteinsDisease phenotypeTuberculosisInfectionDiseaseImmunological diversityChapter 83 Adaptive Immunity and Critical Illness
Schulte W, Maerz L, Moeckel G, Bucala R. Chapter 83 Adaptive Immunity and Critical Illness. 2019, 483-487. DOI: 10.1016/b978-0-323-44942-7.00083-2.Peer-Reviewed Original ResearchAcute kidney injuryCritical illnessEnd-stage renal diseaseChronic kidney diseaseChallenging clinical conditionIschemia-reperfusion injuryComplex disease processAdaptive immune systemAKI pathophysiologyKidney injuryHospitalized patientsRenal diseaseKidney diseaseInflammatory processCommon causeClinical conditionsAdaptive immunityLong-term consequencesDisease processImmune systemSubsequent treatmentInjuryIllnessDiseaseCurrent knowledge
2017
FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease
Roberts S, Leng L, Soroka C, Boyer J, Bucala R, Assis D. FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. Journal Of Hepatology 2017, 66: s363-s364. DOI: 10.1016/s0168-8278(17)31067-x.Peer-Reviewed Original Research
2012
1240 A FUNCTIONAL ROLE OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) FOR FATTY LIVER DISEASE AND OBESITY IN MICE
Heinrichs D, Knauel M, Nellen A, Trautwein C, Bucala R, Bernhagen J, Wasmuth H. 1240 A FUNCTIONAL ROLE OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) FOR FATTY LIVER DISEASE AND OBESITY IN MICE. Journal Of Hepatology 2012, 56: s491. DOI: 10.1016/s0168-8278(12)61252-5.Peer-Reviewed Original Research
2010
P81 MIF-DEFICIENCY REDUCES CHRONIC INFLAMMATION IN ADIPOSE TISSUE AND IMPAIRS INSULIN RESISTANCE AND ASSOCIATED ATHEROSCLEROSIS IN A MODEL OF COMBINED DISEASE
Kleemann R, Verschuren L, Wielinga P, Voshol P, van Erk M, Fingerle-Rowson G, van Dijk K, Ouwens M, Bernhagen J, Bucala R, Kooistra T. P81 MIF-DEFICIENCY REDUCES CHRONIC INFLAMMATION IN ADIPOSE TISSUE AND IMPAIRS INSULIN RESISTANCE AND ASSOCIATED ATHEROSCLEROSIS IN A MODEL OF COMBINED DISEASE. Atherosclerosis Plus 2010, 11: 33. DOI: 10.1016/s1567-5688(10)70148-3.Peer-Reviewed Original Research
2008
350: Macrophage Migration Inhibitory Factor as a New Target in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation
Chang Y, Miklos S, Mueller G, Holler E, Lindner P, Leng L, Schubert T, Bucala R, Hildebrandt G. 350: Macrophage Migration Inhibitory Factor as a New Target in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. Transplantation And Cellular Therapy 2008, 14: 128. DOI: 10.1016/j.bbmt.2007.12.360.Peer-Reviewed Original Research
2001
Characterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients
Al-Abed Y, VanPatten S, Li H, Lawson J, FitzGerald G, Manogue K, Bucala R. Characterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients. Molecular Medicine 2001, 7: 619-623. PMID: 11778651, PMCID: PMC1950073, DOI: 10.1007/bf03401868.Peer-Reviewed Original ResearchConceptsDiabetic patientsDiabetes mellitusPredictor of prognosisBlood glucose levelsNormal patientsGlucose levelsPatientsUseful markerNormal individualsPathologic situationsOxidative stressMellitusAdditional markersΒ-globin chainsLiquid chromatography-mass spectroscopyΒ-chainMarkersHigh levelsPrognosisDiseaseDiagnosisNeuroendocrine properties of macrophage migration inhibitory factor (MIF)
Fingerle‐Rowson G, Bucala R. Neuroendocrine properties of macrophage migration inhibitory factor (MIF). Immunology And Cell Biology 2001, 79: 368-375. PMID: 11488984, DOI: 10.1046/j.1440-1711.2001.01024.x.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorMigration inhibitory factorInhibitory factorCytokine macrophage migration inhibitory factorPro-inflammatory actionsMIF expressionSeptic shockNeuroendocrine mediatorsInflammatory diseasesPathogenic roleEndocrine circuitsNeuroendocrine propertiesImmune systemEndocrine tissuesImmune tissuesNeuroendocrine mechanismsDiseaseTissueArthritisNeuroendocrineFactors
2000
Advanced Glycosylation Endproducts and Diabetic Vascular Disease
Bucala R. Advanced Glycosylation Endproducts and Diabetic Vascular Disease. Developments In Cardiovascular Medicine 2000, 224: 287-303. DOI: 10.1007/978-1-4615-4649-8_15.Peer-Reviewed Original ResearchDiabetic vascular diseaseVascular diseaseAtherosclerotic vascular diseaseClinical pharmacological studiesProgressive vasculopathyOverall morbidityMicrovascular diseaseAnatomic typesPersistent hyperglycemiaDiabetic complicationsEtiologic roleAdvanced glycosylation endproductsBiochemical abnormalitiesDiabetic sequelaeNon-enzymatic glycosylationPharmacological studiesUnderlying causeDiseaseCapillary bedComplicationsBasic laboratoryVasculopathyMorbidityHyperglycemiaRetinopathy
1999
Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs
Zhang X, Bucala R. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. Bioorganic & Medicinal Chemistry Letters 1999, 9: 3193-3198. PMID: 10576686, DOI: 10.1016/s0960-894x(99)00561-2.Peer-Reviewed Original Research
1998
Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features
Bernhagen J, Calandra T, Bucala R. Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. Journal Of Molecular Medicine 1998, 76: 151-161. PMID: 9535548, DOI: 10.1007/s001090050204.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorMigration inhibitory factorInhibitory factorCytokine macrophage migration inhibitory factorDelayed-type hypersensitivity reactionNegative septic shockB cell responsesMIF productionSeptic shockImmunosuppressive effectsHypersensitivity reactionsImmune responseImmunological functionsCell responsesHost macrophagesCritical mediatorGlucocorticoidsMediatorsBiological roleResponseCytokine structureCytokinesDiseaseMacrophagesStress responseProtein Glycation and Diabetic Vascular Disease
Bucala R, Rahbar S. Protein Glycation and Diabetic Vascular Disease. Endocrine Updates 1998, 1: 159-180. DOI: 10.1007/978-1-4615-5569-8_9.Peer-Reviewed Original ResearchVascular diseaseNon-insulin dependent diabeticsAtherosclerotic vascular diseaseEnd-organ complicationsDiabetic vascular diseaseDiabetic glucose controlOverall morbidityDependent diabeticsGlucose controlPersistent hyperglycemiaDiabetic complicationsComplicationsUnderlying causeProtein glycationDiseaseDiabeticsMorbidityHyperglycemiaRetinopathyPatientsMortality
1997
Tobacco smoke is a source of toxic reactive glycation products
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 13915-13920. PMID: 9391127, PMCID: PMC28407, DOI: 10.1073/pnas.94.25.13915.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsTobacco smokeGlycation productsAGE formationSerum AGE levelsIncidence of atherosclerosisPlasma of patientsGlycation end productsRenal insufficiencyCerebrovascular diseaseCigarette smokersHuman smokersHigh prevalenceHigh riskSmokersNonsmokersGlycotoxinsPatientsSpecific fluorescenceSerum proteinsDiseaseCuring of tobaccoAqueous extractSmokeTobacco
1996
Glycation and microglial reaction in lesions of Alzheimer's disease
Dickson D, Sinicropi S, Yen S, Ko L, Mattiace L, Bucala R, Vlassara H. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiology Of Aging 1996, 17: 733-743. PMID: 8892346, DOI: 10.1016/0197-4580(96)00116-9.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAGE immunoreactivityNeurofibrillary tanglesExtracellular neurofibrillary tanglesAmyloid depositsMicroglial reactionActivation of microgliaIntracellular neurofibrillary tanglesAlzheimer's disease brainPattern of immunoreactivityGlycation end productsTriple immunostainingDisease brainSenile plaquesDiffuse amyloidAlzheimer's diseaseImmunoreactivityCryostat sectionsDouble labelingAntibodiesMicrogliaLesionsPolyclonal antibodiesDiseaseGlycation
1995
Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
Beisswenger P, Makita Z, Curphey T, Moore L, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995, 44: 824-829. DOI: 10.2337/diabetes.44.7.824.Peer-Reviewed Original Research
1994
Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease
Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease. Drug Development Research 1994, 32: 77-89. DOI: 10.1002/ddr.430320204.Peer-Reviewed Original ResearchAdvanced glycosylationVascular diseasePhase II clinical trialOxidized low-density lipoproteinSpecific therapeutic modalitiesLow-density lipoproteinDirect toxic effectReversible Schiff base adductsClinical trialsAdvanced glycosylation endproductsTherapeutic modalitiesVascular permeabilityDensity lipoproteinLipoprotein depositionVascular wallELISA techniqueHeterogenous groupPathological effectsEndothelial cellsPharmacological inhibitorsPathological conditionsAgeToxic effectsLipoproteinDisease
1988
Labile T-wave changes caused by respiratory variation in a patient with unstable angina
Bucala R, Loh E, Wang P, Rutherford J. Labile T-wave changes caused by respiratory variation in a patient with unstable angina. International Journal Of Cardiology 1988, 19: 260-262. PMID: 3372087, DOI: 10.1016/0167-5273(88)90087-3.Peer-Reviewed Original Research
1985
Determination of 16 alpha‐hydroxyestrone by radioimmunoassay in systemic lupus erythematosus
Lahita R, Bucala R, Bradlow H, Fishman J. Determination of 16 alpha‐hydroxyestrone by radioimmunoassay in systemic lupus erythematosus. Arthritis & Rheumatism 1985, 28: 1122-1127. PMID: 4052123, DOI: 10.1002/art.1780281007.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusActive diseaseLupus erythematosusInactive systemic lupus erythematosusVariety of seraInactive diseaseSLE patientsAntibody levelsComplement levelsRheumatic diseasesLaboratory criteriaAlpha-hydroxyestroneHormone levelsHealthy volunteersNormal controlsPatientsEstrogenic metabolitesNormal levelsDiseaseErythematosusSignificant increaseRadioimmunoassayPoor correlationMetabolitesHigh levelsRole of Sex Steroids in Systemic Lupus Erythematosus (SLE)
LAHITA R, BUCALA R, BRADLOW H, FISHMAN J. Role of Sex Steroids in Systemic Lupus Erythematosus (SLE). Protides Of The Biological Fluids 1985, 33: 301-304. DOI: 10.1016/b978-0-08-033215-4.50074-1.Peer-Reviewed Original ResearchSystemic lupus erythematosusPathogenesis of SLESex steroidsHydroxylation of estroneLower plasma androgenActive diseaseLupus erythematosusEstrogen metabolismAlpha-hydroxyestroneOxidation of testosteronePlasma androgensPotent estrogenDiseasePathogenesisSteroidsFemalesMalesMetabolismLow levelsErythematosusPatientsAndrogensEstrogenTestosteroneCell membrane